What does the IDSA recommend for treating carbapenem‑resistant Acinetobacter baumannii infections?

Treatment of Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

For CRAB infections, use sulbactam-durlobactam combined with a background carbapenem as first-line therapy when available, as this combination demonstrates the greatest mortality reduction, particularly for pulmonary infections. 1, 2

Primary Treatment Recommendations

First-Line Therapy (When Susceptibility Known)

• Sulbactam-durlobactam plus carbapenem is the preferred regimen, showing superior outcomes in pneumonia and bloodstream infections compared to other available options 1, 2
• This combination has demonstrated consistent mortality reduction in recent clinical trials, unlike traditional agents 2
• The addition of durlobactam inhibits OXA-23 and other β-lactamases, resulting in a 32-fold MIC reduction compared to sulbactam alone 3

Alternative Regimens (When Sulbactam-Durlobactam Unavailable)

High-dose ampicillin-sulbactam-based combinations are the next best option:

• High-dose ampicillin-sulbactam (9g sulbactam component daily) plus high-dose tigecycline is recommended by IDSA as the best alternative for serious CRAB infections 4
• Sulbactam-based regimens consistently show reduced mortality across multiple studies 1, 2
• Always combine with at least one other in vitro active agent 2

Polymyxin-Based Therapy (Last Resort)

When isolates are sensitive only to polymyxins:

• Intravenous polymyxin (colistin or polymyxin B) is strongly recommended 5
• Add adjunctive inhaled colistin for pneumonia cases 5
• Colistin should be administered promptly after mixing with sterile water due to stability concerns 5
• Despite significant nephrotoxicity, polymyxins remain a cornerstone when other options are unavailable 4

Site-Specific Considerations

Pneumonia/VAP

• Sulbactam-durlobactam shows greatest benefit in pulmonary infections 1
• Inhaled colistin provides pharmacokinetic advantages for lung penetration 5
• Avoid tigecycline monotherapy due to suboptimal lung concentrations 1

Bloodstream Infections

• Sulbactam-durlobactam demonstrates promising outcomes 1
• High-dose sulbactam-based combinations remain effective alternatives 2

CNS Infections

• Limited data available; primarily case series 1
• Consider agents with adequate CSF penetration

Agents to AVOID

• Do NOT use tigecycline as monotherapy or primary agent for HAP/VAP caused by Acinetobacter 5
• Do NOT use rifampicin as adjunctive therapy with colistin—no clinical benefit despite increased microbial eradication 5
• Do NOT use aminoglycoside monotherapy 5
• Cefiderocol shows suboptimal outcomes in pulmonary CRAB infections and should be used cautiously 1

Combination Therapy Rationale

• Combination regimens are superior to monotherapy for CRAB infections 4, 2
• Typical combinations include polymyxin with tigecycline, ampicillin-sulbactam, meropenem, or fosfomycin 4
• The preferred combination incorporates sulbactam with at least one other active agent based on susceptibility testing 2

Duration of Therapy

• 7 days of antimicrobial therapy for both HAP and VAP 5
• Adjust duration based on clinical, radiologic, and laboratory improvement 5

Critical Pitfalls to Avoid

• Do not delay appropriate therapy when CRAB is clinically suspected—inappropriate initial coverage significantly worsens outcomes 4
• Do not rely on monotherapy—combination regimens consistently outperform single agents 4, 2
• Do not use standard doses—high-dose regimens (particularly for sulbactam and tigecycline) are essential for adequate tissue penetration 4, 2
• Monitor for PBP3 mutations—these represent the dominant resistance mechanism (81% of nonsusceptible isolates) and can emerge during therapy 3
• Watch for NDM-producing strains—these exhibit elevated MICs to sulbactam-durlobactam and require alternative strategies 3

Emerging Resistance Concerns

• PBP3 substitutions are the primary resistance mechanism to sulbactam-based therapies, confirmed in 81% of nonsusceptible isolates 3
• Novel NDM variants (like NDM-87) show higher resistance to sulbactam-durlobactam 3
• High-risk clones (ST164, ST2) are spreading regionally with diverse resistance mechanisms 3

Consultation Recommendation

Infectious diseases consultation is strongly recommended for all CRAB infections given the complexity of treatment decisions, limited evidence base, and rapidly evolving resistance patterns 6, 2